Skip to main content

Table 1. Correlation between the clinicopathologic characteristics and miR-1296 and SRPK1 expression in HCC (n = 126)

From: MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway

Clinical parameters Cases Expression level P value Expression level P value
MiR-1296high
(n=60)
MiR-1296low
(n=66)
SRPK1high
(n=68)
SRPK1low
(n=58)
Age(years)
 <65 67 31 36 0.746 37 30 0.763
 ≥65 59 29 30   31 28  
Gender
 Male 100 49 51 0.543 55 45 0.649
 Female 26 11 15   13 13  
Tumor size (cm)
 <5 95 46 49 0.752 50 45 0.598
 ≥5 31 14 17   18 13  
Tumor number
 Solitary 107 56 51 0.012* 56 51 0.383
 Multiple 19 4 15   12 7  
Edmondson
 I+II 89 43 46 0.808 47 42 0.686
 III+IV 37 17 20   21 16  
TNM stage
 I+II 99 53 46 0.011* 46 53 0.001*
 III+IV 27 7 20   22 5  
Capsular
 Present 85 41 44 0.842 43 42 0.273
 Absent 41 19 22   25 16  
Venous invasion
 Present 12 2 10 0.024* 11 1 0.006*
 Absent 114 58 56   57 57  
AFP (ng/mL)
 <400 39 17 22 0.544 23 16 0.450
 ≥400 87 43 44   45 42  
HBsAg
 Positive 116 56 60 0.615 61 55 0.466
 Negative 10 4 6   7 3  
  1. HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis. *Statistically significant